Close

Jump to:

  • Navigation
  • Content
  • Footer
Q Doctor hero image

Q Doctor

Follow

Q doctor aims to revolutionise NHS care delivery using video consulting to benefit patients & clinicians

138%
 - 
Funded 30 Jan 2020
£1,000,004 target
£1,386,200 from 520 investors
More
Less

Business overview

Location London, United Kingdom
Social media
Website www.qdoctor.io
Sectors Healthcare Digital Mixed B2B/B2C
Company number 09768044
Incorporation date 8 Sep 2015
More
Less

Investment summary

Type Equity
Valuation (pre-money) £9.2M
Equity offered 13.07%
Tax relief

EIS

  • Idea
  • Key terms
  • Team
  • Updates
  • Investors 520
  • Discussion
  • Documents

Idea

Introduction

- We are transforming the NHS, bringing your care into the modern age. Q doctor addresses a problem that affects everybody.
- We are ahead of the curve, and delivering on a model that keeps modernised NHS care completely free for patients.
- We have a great team working alongside fantastic advisors and investors who are aligned with our values; running a platform designed by clinicians for clinicians in the NHS.

THE PROBLEM

Current statistics suggest that there are one million failed attempts to book a GP appointment every week. In Hospital Outpatients and Urgent Care, appointment levels are also growing yearly with access and clinical delivery being an increasing problem nationwide.

For the NHS, this is a distribution problem - clinicians cannot always be in the right place at the right time. They often need to travel, as do their patients, to interact face-to-face for consultations that could be dealt with remotely.

THE SOLUTION

A video consulting solution that plugs NHS clinicians in to existing NHS infrastructure, allowing them to see NHS patients digitally.

Q doctor, born from an NHS England programme and built by NHS doctors, is now one of the leading regulated providers of video consultation to the NHS. It aims to give patients the control to access their clinician from home or workplace, and allow NHS organisations to place clinical workforce where it is needed, when it is needed, in an empowering way.

Intended impact

Our business model focuses on NHS B2B2C channels and in particular the provision of a flexible SaaS solution (free for the patient). This allows us to utilise existing infrastructure to gain widespread distribution as quickly as possible.

Q doctor has established distribution across Primary, Secondary and Tertiary care, with the nationwide service now available directly and free to millions of people.

Video consultation is named in both the NHS Long Term Plan and the new GP Contract Framework as part of the future. As one of the leading regulated providers of this to the NHS, coupled with rapidly emerging access to Secondary and Urgent Care, we believe Q doctor is poised to continue its strong growth.

Substantial accomplishments to date

- Q doctor is proving its differentiation and product-market fit; now working with hundreds of practices nationwide

- Q doctor has led recent industry firsts in Urgent Care (111/CAS first video use in the NHS) and Outpatient care (Lewisham first specialist use of video consultation nationally) with NHS organisation partners.

- Successful pilots have led to county wide procurement of the Q doctor solution and expansion across geographies and services in recent months.

- Q doctor has grown revenues by 130% in the past year*, with practices and now other NHS organisations approaching Q doctor to digitise their services, filling a large national pipeline.

* Aug 19 - Aug 18. Source: unaudited financial accounts.

Monetisation strategy

The service is free to patients and directly supports the NHS. We currently offer two core services:

1. Q doctor digital platform (SaaS), for use by an organisation such as a practice or a hospital.

2. Q doctor digital locum service; provision of digital locum workforce remotely into a practice.

These are often packaged into a subscription for organisations who wish to have flexibility in their offering from Q doctor.

Importantly, we allow practices to use their own clinicians on the platform to see their own patients; they are the clinicians known and trusted by their patients, and Q doctor acts as an access enabler and workforce solution. Savings are demonstrable; a Clinical Assessment Service recently extrapolated savings of >£43,000 per month and went on the procure the solution in a multi-year county-wide contract.

Use of proceeds

We are looking to raise these funds in order to fulfill our strategy for 2020 and beyond. Our exponential growth in the last 6 months requires more staff support resource, while engineering recruitment will allow us to deliver our technical roadmap for closer NHS integration, along with sales resource converting our expanding national pipeline which includes some of the country's largest NHS healthcare providers.

The following is an approximate breakdown of where we anticipate the funds to be deployed:

Labour: 43%.

Development: 22%.

Operations: 12%.

Marketing: 2%.

Contingency funds: 21%.

Important information

Nesta, the lead investor in this round will receive a class of share (Series A Shares) that enjoys preferential rights to returns and anti-dilution rights. Seedrs investors will receive Ordinary Shares that are expected to be eligible for EIS tax relief.

On a distribution of assets to investors, available funds will be distributed in the following order:

(1) The preferred shareholders will receive the amount they invested.
(2) All other investors -- including Seedrs investors -- will receive the amount they invested.
(3) The preferred shareholders will receive an amount equal to 5% per annum accruing on a daily basis on the amount paid for their shares.
(4) Remaining funds will be distributed to all shareholders on a pro rata basis.

The anti-dilution right attaching to the Series A Shares means that if the company raises a future round at a share price that is lower than the share price in this round, further shares will be issued to the Series A shareholders, which would dilute Seedrs investors.

Loading, please wait...

Open an account to get access to the team members of Q Doctor

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This webpage has been approved as a financial promotion by Seedrs Limited ("Seedrs"), which is authorised and regulated by the Financial Conduct Authority. It is not intended to be a promotion of any individual investment opportunity and is not an offer to the public. The summary information provided about investment opportunities on this webpage is intended solely to demonstrate the types of investments available on the Seedrs platform, and any investment decision should be made on the basis of the full campaign. Full campaigns are available to investors who have become authorised to invest on the Seedrs platform. All investment activities take place within the United Kingdom, and any person resident outside the United Kingdom should ensure that they are not subject to any local regulations before investing.

Seedrs does not make investment recommendations to you. No communications from Seedrs, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Seedrs does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Seedrs, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £9,223,378

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

Pitch type

There are 5 types of investment pitch available on Seedrs.

  • Equity
  • Convertible
  • Fund
  • Cohort
  • Secondary

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Seedrs campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Warning

You are following a link outside of www.seedrs.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Seedrs.

ContinueCancel